CD14 and neoplasm: Interestingly, we observe that the presence of a tumour within the engineered TME leads to the transformation of normal immunostimulatory cDC2s into CD14+ DCs, with a phenotype matching their in vivo counterpart and an impaired ability to stimulate T-cell proliferation.